New drug targets hard-to-treat KRAS cancers in early trial
Disease control
Recruiting now
This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…
Phase: PHASE1, PHASE2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC